SEC Form 4 · accession 0000914190-16-000841
Arno Therapeutics, Inc · ARNI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M Tanen
Officer — Secretary · Director
Period of report
Oct 3, 2016
Accepted (ET)
Oct 5, 2016 · 5:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001195116
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF3 | Oct 3, 2016 | P$0 | 142,857 | — | A | 314,569 | D | |
| Common StockF1 | holding | — | — | — | 362,015 | I | By Trust | |
| Common StockF2 | holding | — | — | — | 18,691 | I | By spouse for minor children |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016 Series F Warrants (right to buy)F3 | $0.4375 | Oct 3, 2016 | P | 71,428 | A | Oct 3, 2016 | Oct 3, 2021 | Common Stock | 71,428 | 71,428 | D |
| Stock Option (right to buy)F4 | $8.00 | holding | — | — | — | — | Sep 29, 2019 | Common Stock | 1,250 | 1,250 | D |
| Stock Option (right to buy)F4 | $8.00 | holding | — | — | — | — | Nov 5, 2020 | Common Stock | 1,250 | 1,250 | D |
| Stock Option (right to buy)F5 | $2.40 | holding | — | — | — | — | Nov 4, 2023 | Common Stock | 68,448 | 68,448 | D |
| Stock Option (right to buy)F4 | $2.90 | holding | — | — | — | — | Jan 24, 2024 | Common Stock | 34,224 | 34,224 | D |
| Stock Option (right to buy)F6 | $0.37 | holding | — | — | — | — | Apr 7, 2026 | Common Stock | 88,628 | 88,628 | D |
Explanation of responses
- F1Held by the David M. Tanen Revocable Grantor Trust, of which the Reporting Person is a beneficiary.
- F2Held by the Reporting Person's spouse as custodian for the benefit of their minor children under the Uniform Gift to Minors Act. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
- F3The reported securities are included within 142,857 units of the Issuer's securities that the Reporting Person committed to purchase, at a per unit price of $0.35, pursuant to the Securities Purchase Agreement dated 8/15/16, a copy of which was filed as Exhibit 10.1 to the Issuer's Form 8-K filed 8/16/16.
- F4Currently exercisable.
- F5Vests in equal 36-monthly installments commencing 12/4/13.
- F6Vests in equal 12-monthly installments commencing 5/7/16.